Conversely, DKD in type 2 diabetes mellitus shows greater pathological heterogeneity, with some people developing classical glomerular lesions, while others present with atypical features such as prominent tubulointerstitial damage, vascular abnormalities, or coexisting non-DKD pathology [21,22]
The medication will change how you experience hunger and how your body processes food, which means your usual approaches might need significant modification
These approaches give you and your doctor a chance to monitor how your hunger, weight and metabolic markers respond
doi.org/10.1111/dom.15728 4 Tinsley GM, Nadolsky S
Do GLP-1 patches (berberine patches) work for weight loss
Q4 2026 (earliest): NDA filing with the FDA for the weight-management indication